159 related articles for article (PubMed ID: 32541317)
1. Medical treatment of advanced malignant perivascular epithelioid cell tumors.
Fabbroni C; Sbaraglia M; Sanfilippo R
Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317
[TBL] [Abstract][Full Text] [Related]
2. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
5. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
6. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
[TBL] [Abstract][Full Text] [Related]
7. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
8. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester M; Dolnik A; Kornak U; Pfitzner B; Hummel M; Treue D; Hartmann A; Agaimy A; Weyerer V; Lekaj A; Brakemeier S; Peters R; Öllinger R; Märdian S; Bullinger L; Striefler JK; Flörcken A
J Pathol Clin Res; 2021 Jan; 7(1):3-9. PubMed ID: 33180365
[TBL] [Abstract][Full Text] [Related]
9. Complexity of PEComas : Diagnostic approach, molecular background, clinical management.
Utpatel K; Calvisi DF; Köhler G; Kühnel T; Niesel A; Verloh N; Vogelhuber M; Neu R; Hosten N; Schildhaus HU; Dietmaier W; Evert M
Pathologe; 2020 Jun; 41(Suppl 1):9-19. PubMed ID: 31309284
[TBL] [Abstract][Full Text] [Related]
10. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa S; Bui NQ; Ganjoo KN
Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
12. Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications.
Agaram NP; Sung YS; Zhang L; Chen CL; Chen HW; Singer S; Dickson MA; Berger MF; Antonescu CR
Am J Surg Pathol; 2015 Jun; 39(6):813-25. PubMed ID: 25651471
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics.
Cohen PR; Kato SM; Erickson CP; Calame A; Kurzrock R
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499412
[TBL] [Abstract][Full Text] [Related]
14. Expanding the histomorphologic spectrum of TFE3-rearranged perivascular epithelioid cell tumors.
Maloney N; Giannikou K; Lefferts J; Bridge JA; Linos K
Hum Pathol; 2018 Dec; 82():125-130. PubMed ID: 29626599
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
[TBL] [Abstract][Full Text] [Related]
16. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
17. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.
Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE
Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101
[TBL] [Abstract][Full Text] [Related]
18. Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature.
Alaggio R; Cecchetto G; Martignoni G; Bisogno G; Cheng L; Sperlì D; d'Amore ES; Dall'Igna P
J Pediatr Surg; 2012 Jun; 47(6):e31-40. PubMed ID: 22703822
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.
Akumalla S; Madison R; Lin DI; Schrock AB; Yakirevich E; Rosenzweig M; Balar AV; Frampton GM; Edgerly C; Erlich RL; Miller VA; Ganesan S; Ross JS; Ali SM
Oncology; 2020; 98(12):905-912. PubMed ID: 32966992
[TBL] [Abstract][Full Text] [Related]
20. TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract.
Vannucchi M; Minervini A; Salvi M; Montironi R; Raspollini MR
Clin Genitourin Cancer; 2020 Dec; 18(6):e692-e697. PubMed ID: 32576448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
